COVID-19 vaccine maker Novavax (NASDAQ: NVAX) has been a volatile stock to own over the past year. If it flops and the company doesn't obtain Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in the coming months, shares of the healthcare company could nosedive even further. Last week, Politico published an article that suggested manufacturing issues could delay the production of Novavax's COVID-19 vaccine -- again.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting